Raves and Risks for Erythropoietin

Overview

Journal Cytokine Growth Factor Rev

Date 2008 Feb 27

PMID 18299246

Citations 60

Authors

Kenneth Maiese

Zhao Zhong Chong

Yan Chen Shang

Affiliations

Soon will be listed here.

Abstract

Global use of erythropoietin (EPO) continues to increase as a proven agent for the treatment of anemia. Yet, EPO is no longer believed to have exclusive biological activity in the hematopoietic system and is now considered applicable for a variety of disorders such as diabetes, Alzheimer's disease, and cardiovascular disease. Treatment with EPO is considered to be robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. On the converse side, observations that EPO administration is not without risk have fueled controversy. Here we present recent advances that have elucidated a number of novel cellular pathways governed by EPO to open new therapeutic avenues for this agent and avert its potential deleterious effects.

Citing Articles

Innovative therapeutic strategies for cardiovascular disease.

Maiese K EXCLI J. 2023; 22:690-715.

PMID: 37593239 PMC: 10427777. DOI: 10.17179/excli2023-6306.

Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System.

Maiese K Biomolecules. 2023; 13(5).

PMID: 37238686 PMC: 10216724. DOI: 10.3390/biom13050816.

The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor.

Knorr D, Rodriguez Polo I, Pies H, Schwedhelm-Domeyer N, Pauls S, Behr R Front Mol Neurosci. 2023; 16:1154509.

PMID: 37168680 PMC: 10165946. DOI: 10.3389/fnmol.2023.1154509.

Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm.

Maiese K Front Biosci (Landmark Ed). 2021; 26(9):614-627.

PMID: 34590471 PMC: 8756734. DOI: 10.52586/4971.

Cognitive Impairment and Dementia: Gaining Insight through Circadian Clock Gene Pathways.

Maiese K Biomolecules. 2021; 11(7).

PMID: 34356626 PMC: 8301848. DOI: 10.3390/biom11071002.

References

Rowe M, Wiest C, Chuang D . GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007; 31(6):920-31. PMC: 2020444. DOI: 10.1016/j.neubiorev.2007.03.002. View

Teramo K, Kari M, Eronen M, Markkanen H, Hiilesmaa V . High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia. 2004; 47(10):1695-703. DOI: 10.1007/s00125-004-1515-3. View

Contaldo C, Meier C, Elsherbiny A, Harder Y, Trentz O, Menger M . Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice. Am J Physiol Heart Circ Physiol. 2007; 293(1):H274-83. DOI: 10.1152/ajpheart.01031.2006. View

Sathyanarayana P, Menon M, Bogacheva O, Bogachev O, Niss K, Kapelle W . Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood. 2007; 110(2):509-18. PMC: 1924484. DOI: 10.1182/blood-2006-11-056465. View

Diamanti-Kandarakis E, Konstantinopoulos P, Papailiou J, Kandarakis S, Andreopoulos A, Sykiotis G . Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med. 2005; 35(10):831-40. DOI: 10.2165/00007256-200535100-00001. View

Eliopoulos N, Gagnon R, Francois M, Galipeau J . Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol. 2006; 17(6):1576-84. DOI: 10.1681/ASN.2005101035. View

Chong Z, Kang J, Maiese K . Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003; 23(3):320-30. DOI: 10.1097/01.WCB.0000050061.57184.AE. View

Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A . Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006; 152(6):1096.e9-15. DOI: 10.1016/j.ahj.2006.08.005. View

Keogh C, Yu S, Wei L . The effect of recombinant human erythropoietin on neurovasculature repair after focal ischemic stroke in neonatal rats. J Pharmacol Exp Ther. 2007; 322(2):521-8. DOI: 10.1124/jpet.107.121392. View

10.

Chong Z, Li F, Maiese K . Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005; 75(3):207-46. DOI: 10.1016/j.pneurobio.2005.02.004. View

11.

Chong Z, Li F, Maiese K . The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med. 2007; 19(2):263-72. PMC: 1986680. View

12.

Kang J, Chong Z, Maiese K . Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res. 2003; 74(1):37-51. DOI: 10.1002/jnr.10740. View

13.

Ceelen W, Boterberg T, Smeets P, Van Damme N, Demetter P, Zwaenepoel O . Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels. Br J Cancer. 2007; 96(5):692-700. PMC: 2360077. DOI: 10.1038/sj.bjc.6603568. View

14.

Li F, Chong Z, Maiese K . Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res. 2006; 3(3):187-201. PMC: 1986678. DOI: 10.2174/156720206778018758. View

15.

Assaraf M, Diaz Z, Liberman A, Miller Jr W, Arvanitakis Z, Li Y . Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol. 2007; 66(5):389-98. DOI: 10.1097/nen.0b013e3180517b28. View

16.

Westenbrink B, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, du Marchie Sarvaas G . Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007; 28(16):2018-27. DOI: 10.1093/eurheartj/ehm177. View

17.

Maiese K, Chong Z, Shang Y . Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem. 2007; 14(16):1729-38. PMC: 2447161. DOI: 10.2174/092986707781058968. View

18.

Wu Y, Shang Y, Sun S, Liang H, Liu R . Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis. 2007; 12(8):1365-75. DOI: 10.1007/s10495-007-0065-9. View

19.

Mikati M, El Hokayem J, El Sabban M . Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. Epilepsia. 2007; 48(1):175-81. DOI: 10.1111/j.1528-1167.2006.00900.x. View

20.

Gao E, Boucher M, Chuprun J, Zhou R, Eckhart A, Koch W . Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007; 293(1):H60-8. DOI: 10.1152/ajpheart.00227.2007. View